The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Reducing the risk of cardiovascular toxicities when treating hematological malignancies
In this video, Alexander Lyon, MD, PhD, Imperial College London, London, UK, discusses the important link between cardiology and oncology, drawing focus on how therapeutic agents used in the treatment of hematological malignancies can result in cardiovascular toxicities which must be monitored. Dr Lyon first explains that despite the increased risk of toxicities associated with novel therapeutic agents, cardio-protective medication can be given to patients upfront to prevent these from occurring. Dr Lyon then discusses the baseline risk assessment performers that were produced by a team of cardiologists, oncologists, and hematologists to better assess patient risk for cardiac toxicities following treatment. To conclude, Dr Lyon emphasizes the importance of cardiologists and oncologists communicating clearly to reduce the risk of toxicities and improve outcomes for patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
